文献速递慢性肾脏病急性肾损伤血液净化与透析

CKD患者肾功能下降与严重药物不良反应风险

Kidney Function Decline and Serious Adverse Drug Reactions in Patients With CKD.
PubMed 文献 · Am J Kidney Dis · 2023-11-10

一项法国CKD-REIN前瞻性队列研究纳入3033例中晚期CKD肾病科门诊患者,中位随访4.7年,360例发生488次严重药物不良反应,肾脏和泌尿系统疾病与出血各占170次,多数导致住院,基线eGFR每降低1mL/min/1.73m2,急性肾损伤风险升高2.2%、出血性药物不良反应风险升高8%。

要点

  • 严重药物不良反应以药物性急性肾损伤和出血最常见,抗血栓药与RAS抑制剂为主。
  • 基线eGFR每降低1mL/min/1.73m2,急性肾损伤风险升高2.2%,出血风险升高8%。
  • 超过27%的严重药物不良反应可预防或潜在可预防。

核心结论

  • 药物不良反应是CKD患者住院的主要原因,较低eGFR水平是严重药物不良反应的主要危险因素。

研究设计与样本

  • 前瞻性队列研究,纳入法国CKD-REIN队列3033例中晚期CKD肾病科门诊患者,中位随访4.7年。

主要发现

  • 随访期间360例患者发生488次严重药物不良反应,肾脏和泌尿系统疾病170次、出血170次,合计占70%。
  • 常见药物类别为抗血栓药和肾素-血管紧张素系统抑制剂。
  • 488次严重药物不良反应中多数与住院相关(467次),32次直接或间接与死亡相关,22次与危及生命事件相关。
  • 488次严重药物不良反应中超过27%可预防或潜在可预防。
  • 基线eGFR每降低1mL/min/1.73m2,急性肾损伤风险升高2.2%,出血性药物不良反应风险升高8%。

临床怎么用

  • 处方药物时需监测肾功能,尤其抗血栓药等高风险药物。

局限性

  • 结果不能外推至非肾病科医生治疗的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Adverse drug reactions (ADRs) are common in patients with chronic kidney disease (CKD). The impact of kidney function decline on serious ADR risk has been poorly investigated. We comprehensively describe ADRs and assess the relationship between estimated glomerular filtration rate (eGFR) and serious ADR risk. STUDY DESIGN: Prospective cohort study. SETTING & PARTICIPANTS: 3,033 participants in French Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN) cohort study, a nationwide sample of nephrology outpatients with moderate to advanced CKD. PREDICTORS: Demographic and biological data (including eGFR), medication prescriptions. OUTCOME: ADRs (preventable or not) were prospectively identified from hospital discharge reports, medical records, and patient interviews. Expert pharmacologists used validated tools to adjudicate ADRs. ANALYTICAL APPROACH: Restricted cubic splines in fully adjusted cause-specific Cox proportional hazard models were used to evaluate the relationship between eGFR and the risk of serious ADRs (overall and by subtype). RESULTS: During a median follow-up period of 4.7 years, 360 patients experienced 488 serious ADRs. Kidney and urinary disorders (n=170) and hemorrhage (n=170) accounted for 70% of serious ADRs. The most common medications classes were antithrombotics and renin-angiotensin system inhibitors. The majority of those serious ADRs were associated with hospitalization (n=467), with 32 directly or indirectly associated with death and 22 associated with a life-threatening event. More than 27% of the 488 serious ADRs were preventable or potentially preventable. The eGFR is a major risk factor for serious ADRs. The risk of acute kidney injury was 2.2% higher and risk of bleeding ADRs was 8% higher for each 1mL/min/1.73m2 lower baseline eGFR. LIMITATIONS: The results cannot be extrapolated to patients who are not being treated by a nephrologist. CONCLUSIONS: ADRs constitute a major cause of hospitalization in CKD patients for whom lower eGFR level is a major risk factor. PLAIN-LANGUAGE SUMMARY: Patients with chronic kidney disease (CKD) have complex clinical presentations, take multiple medications, and often receive inappropriate prescriptions. Using data from a large, prospective CKD cohort, we found a high incidence of serious adverse drug reactions (ADRs). The 2 most common serious ADRs were drug-induced acute kidney injury and bleeding. A large proportion of serious ADRs required hospital admission, and 11% led to death or were life threatening. Lower kidney function was a major risk factor for serious ADRs. Many of these serious ADRs were determined to be partly preventable through greater adherence to prescription guidelines. This report enhances our understanding of the potential toxicity of drugs taken by patients with moderate to advanced CKD. It emphasizes the importance of monitoring kidney function when prescribing drugs, particularly for high-risk medications such as antithrombotic agents.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Laville SM, Gras-Champel V, Hamroun A, et al. Kidney Function Decline and Serious Adverse Drug Reactions in Patients With CKD. Am J Kidney Dis. 2023. PMID: 37951340. doi:10.1053/j.ajkd.2023.09.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。